Sparked by the dismissal of its complaint against Astra Zeneca and Sanofi by the government’s Administrative Dispute Resolution Panel (ADR), the National Association of Community Health Centers say “they cannot wait any longer for a solution,” to the two-year standoff
…
The Biden administration is requesting $27 billion to combat monkeypox and COVID-19 as part of a stopgap spending bill to fund the government past the end of fiscal year 2022, which ends Sept. 30. Senate Republicans are signaling skepticism and
…
U.S. Health and Human Services Secretary Xavier Becerra told members of Congress on Thursday that his department is doing all it can with the tools it has to address drug manufacturers’ denials of 340B pricing involving contract pharmacies.
If lawmakers
…
Top U.S. House Republicans sent U.S. Health and Human Services Secretary Xavier Becerra a letter on Monday asking 18 detailed questions about implementation and oversight of the Inflation Reduction Act’s (IRA) Medicare drug price negotiation provisions. Their interrogation foreshadows intensified
…
The landmark prescription drug pricing legislation that President Joe Biden signed this month is a mixed bag for 340B stakeholders, 340B Health Publisher and CEO Ted Slafsky says in his latest column for Omnicell.
Biden signed the Inflation Reduction Act on
…
U.S. Rep. Bruce Westerman (R-Ark.) has reintroduced a comprehensive health care bill he sponsored during the last session of Congress that would create new reporting requirements for 340B disproportionate share (DSH), children’s, and free-standing cancer hospitals and their child sites.
…
Elise Stefanik (R-N.Y.), U.S. congresswoman for the 21st district in upstate New York and third highest-ranking Republican in the House of Representatives, visited independently-owned Condo Pharmacy in Plattsburgh, N.Y., last week in a show of support for the 340B contract pharmacy
…
President Joe Biden this afternoon is scheduled to sign legislation that for the first time will let Medicare negotiate the prices of certain costly prescription drugs and require drug makers to pay Medicare rebates when their prices outpace inflation.
House
…
The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
The committee included the directive to the U.S. Health Resources and
…
The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.
But
…*Sign up for news summaries and alerts from 340B Report